Join

Compare · CRBU vs GILD

CRBU vs GILD

Side-by-side comparison of Caribou Biosciences Inc. (CRBU) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CRBU and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $155.82B, about 853.8x CRBU ($182.5M).
  • Over the past year, CRBU is up 45.1% and GILD is up 10.3% - CRBU leads by 34.8 points.
  • GILD has been more active in the news (20 items in the past 4 weeks vs 2 for CRBU).
  • GILD has more recent analyst coverage (25 ratings vs 12 for CRBU).
PerformanceCRBU+45.12%GILD+10.34%
2025-06-10+0.00%2026-06-10
MetricCRBUGILD
Company
Caribou Biosciences Inc.
Gilead Sciences Inc.
Price
$1.78-3.25%
$121.46-3.19%
Market cap
$182.5M
$155.82B
1M return
-11.85%
-9.06%
1Y return
+45.12%
+10.34%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2021
1992
News (4w)
2
20
Recent ratings
12
25
GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Latest CRBU

Latest GILD